Deepbridge launches two new propositions

Deepbridge has today announced the launch of two new propositions.

Deepbridge currently operates the evergreen Deepbridge Technology Growth EIS and, in addition, has today launched the Deepbridge Life Sciences SEIS and the Deepbridge IHT Service.

Led by eminent bio-entrepreneur and surgeon Professor Chris Wood, the Deepbridge Life Sciences SEIS is a ten company proposition, offering investors with a diversified portfolio of life sciences investment opportunities and the tax benefits potentially available under SEIS.

The overarching focus of the Deepbridge Life Sciences SEIS is to provide investment opportunities in companies that aim to satisfy the needs of large and growing markets, by being engaged in the discovery and development of therapeutics for; anti-viral drugs, antibiotic drug, neurodegenerative disease therapeutics, cancer diagnostics/therapeutics and autoimmune and other metabolic disorder therapies.

The Deepbridge IHT Service builds on Deepbridge’s experience in the renewable energy sector, following successful fund raising under the now closed Deepbridge Renewable Energy EIS and Deepbridge Hydro EIS, and invests in Business Relief qualifying asset-backed renewable energy opportunities that benefit from contractual revenues available under the Renewables Obligation; potentially exempting a portion of the Investor’s estate from IHT, after a two-year holding period.

Both propositions will continue Deepbridge’s commitment to not charge fees to the investor, thereby ensuring maximum share allocation and the maximising of potential tax reliefs.

Ian Warwick, Managing Director at Deepbridge, commented:

“We are delighted with the feedback received from advisers even before we launch these new propositions. The overwhelming response from advisers has been that they are looking for a credible diversified portfolio approach to SEIS. We are delighted that Professor Chris Wood will be leading this proposition and believe that the opportunity to back Chris and his team is an appealing factor for advisers and investors.

“We are also pleased to be continuing to invest in the renewable energy space.  Knowing this sector well; we believe that it is a great opportunity for a Business Relief proposition, due to the asset-backed and Government subsidised nature of the investment.  We have been frustrated by the propositions in the Business Relief market which use capital preservation as an excuse for limiting the income opportunities for investors. Due to the predictable nature of our renewable energy projects, we know that we can look to preserve capital whilst also offering investors the option of a target 6% annual yield.

“Deepbridge continues to grow and we are pleased with the feedback we receive from advisers and investors alike that they appreciate our commercial and transparent approach.”



Keith Taylor, Managing Director at Taylor Frost Wealth Management, commented:

“We welcome the launch of the Deepbridge Life Sciences SEIS as a credible SEIS solution for some of our clients.  We provide financial advice to a number of medical practitioners and these clients have an understanding of the types of investment being made and the potential opportunities life science investments can offer.  The generous tax incentives available under SEIS are also appealing as well as the Deepbridge approach of taking their fees from the investee companies in order that the investor’s money is 100% eligible for any potential tax reliefs.”